Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOCH: Eribulin and Pembrolizumab in Tubo-Ovarian and Uterine Carcinosarcoma
NCT05619913Phase 2Completed
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of eribulin, pembrolizumab in ovarian carcinosarcoma (OCS), uterine carcinosarcoma (UCS), sponsored by Australia New Zealand Gynaecological Oncology Group. Started May 2023; status: completed.
02
Drugs
eribulinpembrolizumab
03
Conditions
ovarian carcinosarcoma (OCS)uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT05619913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619913.